Drug Development Pharma - February 6, 2014
AstraZeneca cuts another 550 jobs
On February 6 AstraZeneca released its full quarter and full year results 2013 where it stood clear that the company expects another 550 layoffs due to savings. Of the 550 jobs, 168 of them will be cut off as the R&D unit in Avishkar (Bangalore, India) is closed down. The remaining 400 posts will be […]
Biotech Business - February 6, 2014
BerGenBio completes NOK75 million private placement
The oncology biopharmaceutical company announces that it has raised NOK75 million (c.$12.5 million) from a syndicate of new and existing investors through a private placement. This follows a $6.0 million round in May 2013. According to BerGenBio proceeds from the financing will be used to support the development of the company’s portfolio of innovative cancer […]
Collaboration - February 5, 2014
Life science companies form new network
Recipharm, Cobra Biologics and Syntagon team up with five other companies in a new network to undertake the distortion of competition on the market. The new initiative is called LSIS, Life Science Innovation Support, and is formed to assure fair competition between private and public players. The background to the new formation is according to a […]
Drug Development Pharma - February 5, 2014
SMEs drive behind innovative medicine
Over 40% of innovative medicines recommended for marketing authorisation in the European Union between 2010 and 2012 originated from small or medium-sized enterprises, says EMA. According to an article published recently in Nature Reviews Drug Discovery, authored by staff members of the European Medicines. Agency (EMA), small or medium-sized enterprises (SMEs), academia, public bodies and […]
Collaboration - February 5, 2014
Saromics and Bioversys tackle antimicrobial resistance
Swedish Saromics Biostructures join forces with Swiss Bioversys to fight against multidrug-resistant bacterial infections. The two companies will collaborate in an international project supported by the European initiative Eurostars. Saromics Biostructures and Bioversys will combine technology modules, expertise and resources to drive the drug development process of initial hit molecules towards fully characterized lead molecules that qualify […]
Uncategorized - February 4, 2014
Better methods provide new drugs faster
Methods for more effective design of clinical trials have been investigated in a new dissertation from Gothenburg University. Since many studies are formed and analyzed through statistical methods, it also implies that better statistics lead to reduced costs for the development of new drugs, according to the findings. Better statistical methods can also speed up […]
